Opportunities and challenges in the development of kinase inhibitor therapy for cancer

被引：147

作者：

Sawyers, CL ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA

[5] Univ Calif Los Angeles, Jonsson Canc Ctr, Los Angeles, CA 90095 USA

[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

GENES & DEVELOPMENT | 2003年 / 17卷 / 24期

关键词：

D O I：

10.1101/gad.1152403

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

引用

页码：2998 / 3010

页数：13

共 101 条

[1] Identification of TOR signaling complexes: more TORC for the cell growth engine [J].

Abraham, RT .

CELL, 2002, 111 (01) :9-12

[2] ALTERATIONS IN THE P53 GENE AND THE CLONAL EVOLUTION OF THE BLAST CRISIS OF CHRONIC MYELOCYTIC-LEUKEMIA [J].

AHUJA, H ;

BARELI, M ;

ADVANI, SH ;

BENCHIMOL, S ;

CLINE, MJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6783-6787

[3]

Allander SV, 2001, CANCER RES, V61, P8624

[4] Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor [J].

Antonyak, MA ;

Moscatello, DK ;

Wong, AJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2817-2822

[5] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[6] Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].

Armstrong, SA ;

Kung, AL ;

Mabon, ME ;

Silverman, LB ;

Stam, RW ;

Den Boer, ML ;

Pieters, R ;

Kersey, JH ;

Sallan, SE ;

Fletcher, JA ;

Golub, TR ;

Griffin, JD ;

Korsmeyer, SJ .

CANCER CELL, 2003, 3 (02) :173-183

[7] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].

Azam, M ;

Latek, RR ;

Daley, GQ .

CELL, 2003, 112 (06) :831-843

[8] Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[9] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[10] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

← 1 2 3 4 5 6 7 8 9 10 →